Anixa Biosciences (ANIX)

Its cancer vaccine activities include candidates being studied for the prevention or treatment of breast and ovarian cancer, as well as broader research into vaccines for other difficult, high-incidence malignancies such as lung, colon, and prostate cancer. These programmes are intended to move beyond traditional therapeutic approaches by training immune responses against biological features linked to cancer development or recurrence. As with many early-stage biotechnology companies, Anixa’s value proposition depends heavily on clinical progress, regulatory outcomes, intellectual property, and the ability to secure development partnerships or funding.

Anixa also develops CAR-T therapy technology through its subsidiary Certainty Therapeutics, Inc. The company’s ovarian cancer programme, liraltagene autoleucel, also known as lira-cel, uses a chimeric endocrine receptor T-cell approach. This strategy differs from conventional CAR-T designs by targeting a hormone-receptor pathway associated with ovarian cancer, aiming to adapt the success of cell therapy in blood cancers to a solid tumour setting.

The company also retains a smaller legacy segment that includes limited patent licensing activities. For investors, Anixa represents a high-risk, research-driven biotech stock tied to oncology innovation, clinical trial execution, and the long development timelines typical of novel cancer therapeutics and vaccines.